ADiTx Therapeutics, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. ADiTx Therapeutics has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
IPO Year: 2020
Exchange: NASDAQ
Website: aditxt.com
DEF 14A - Aditxt, Inc. (0001726711) (Filer)
PRER14A - Aditxt, Inc. (0001726711) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
8-K/A - Aditxt, Inc. (0001726711) (Filer)
424B3 - Aditxt, Inc. (0001726711) (Filer)
EFFECT - Aditxt, Inc. (0001726711) (Filer)
8-K - Aditxt, Inc. (0001726711) (Filer)
PRER14A - Aditxt, Inc. (0001726711) (Filer)
S-1/A - Aditxt, Inc. (0001726711) (Filer)
PRE 14A - Aditxt, Inc. (0001726711) (Filer)
Dawson James initiated coverage of ADiTx Therapeutics with a rating of Buy
— Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases — — Hello Alpha partnership boosts awareness of and access to Phexxi for millions of women — SAN DIEGO, June 27, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM) today announced a new market partnership with Hello Alpha, a telemedicine company with a medical team specifically trained for a woman's unique needs, to offer Phexxi® (lactic acid, citric acid and potassium bitartrate), the non-hormonal prescription vaginal gel FDA-approved to prevent pregnancy for those who choose to use an on-demand method of birth control.
-- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly issued patent is Evofem's fifth covering Hormone-Free "In the Moment" Contraceptive Phexxi in the United States -- SAN DIEGO, June 11, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,992,472, which covers composition and methods for contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"
SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Received $1 million from Aditxt, Inc. (NASDAQ:ADTX) in May 2024 in consideration for reinstating and amending
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities purchase agreements for the purchase and sale of an aggregate of 4,186 shares of the Company's Series C-1 Convertible Preferred Stock, 4,186 shares of the Company's D-1 Preferred Stock, and warrants to purchase approximately 1.65 million shares of common stock in a private placement priced at-the-market under Nasdaq rules. The shares of Series C-1 Convertible Preferred Stock have a stated value of $1,000 per share. They are initially convertible into an aggregate of approximately 1.65 million
Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical formulation Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive arrangement agreement ("Arrangement Agreement") to acquire Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. Under the Arrangement Agreement, Aditxt's wholly owned subsidiary, A
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") pursuant to which Aditxt Inc. (NASDAQ:ADTX) ("Aditxt"), a Richmond, Virginia- b
-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch -- SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofe
— Medi-Cal serves more than 15.4 million Californians — — 7.4% improvement in Phexxi rebate to take effect July 1, 2024 — SAN DIEGO, March 20, 2024 /PRNewswire/ -- Commercial-stage women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFMD) today announced that it has successfully renegotiated the rebate for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free, woman-controlled contraceptive, with Medi-Cal, the California state Medicaid program. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">
-- New weight loss drugs like Ozempic, Wegovy and Zepboundmay make oral birth control pills less effective at certain points -- SAN DIEGO, March 7, 2024 /PRNewswire/ -- Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone.1 Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity.2 These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more likely.
Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced More Than 60% from 2022 Levels SAN DIEGO, Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi® (lactic acid, citric acid, and potassium bitartrate), its hormone-free contraceptive gel, and the Company's lowest total operating expenses since becoming a commercial stage company in 2020. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">
- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio --- Newly issued patent is Evofem's fifth covering Hormone-Free "In the Moment" Contraceptive Phexxi in the United States
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities purchase agreements for the purchase and sale of an aggregate of 4,186 shares of the Company's Series C-1 Convertible Preferred Stock, 4,186 shares of the Company's D-1 Preferred Stock, and warrants to purchase approximately 1.65 million shares of common stock in a private placement priced at-the-market under Nasdaq rules.The shares of Series C-1 Convertible Preferred Stock have a stated value of $1,000 per share. They are initially convertible into an aggregate of approximately 1.65 million sha
-8-K
Shares of Stryve Foods, Inc. (NASDAQ:SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss. Stryve Foods posted adjusted loss of $1.90 per share, versus market estimates for a loss of $1.96 per share. The company’s sales came in at $2.887 million versus expectations of $5.009 million, according to data from Benzinga Pro. Stryve Foods shares dipped 25.2% to $1.0965 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers VivoPower International PLC (NASDAQ:VVPR) shares surged 315% to $6.10 after the company's Tembo subsidiary announced it will merge with the Nasdaq-listed Cactus Acquisition Corp. 1 Limited. Trio Petroleum Corp. (
Aditxt, Inc. (NASDAQ:ADTX) shares are volatile Tuesday after the company announced it will acquire Appili Therapeutics. The Details: Aditxt’s wholly owned subsidiary, Adivir, Inc. will acquire all issued and outstanding Class A common shares of Appili in the transaction. Appili has developed FDA-approved Likmez (previously ATI-1501), its ATI-1701 biodefense program supported by a USD $14 million non-dilutive award from the U.S Department of Defense, and its ATI-1801 topical formulation targeting cutaneous leishmaniasis. Aditxt shares are moving on heavy trading volume following the announcement. According to data from Benzinga Pro, more than 12 million shares have already been
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 47.9% to $2.81 during Tuesday's regular session. The market value of their outstanding shares is at $20.4 million. MSP Recovery (NASDAQ:LIFW) shares moved upwards by 33.26% to $0.89. The market value of their outstanding shares is at $13.1 million. Aditxt (NASDAQ:ADTX) shares increased by 19.09% to $3.79. The market value of their outstanding shares is at $6.3 million. Q32 Bio (NASDAQ:QTTB) shares increased by 17.69% to $21.18. The company's market cap stands at $252.7 million. Evaxion Biotech (NASDAQ:EVAX) stock rose 16.4% to $3.76. The market value of their outstanding shares is at $18.0 million. As per the news, the Q4 earnin
Under the terms of the Arrangement Agreement, shareholders of Appili (the "Appili Shareholders") will receive (i) 0.002745004 of a share of common stock (each whole share, an "Aditxt Share") of Aditxt (the "Share Consideration") and (ii) US$0.0467 (or approximately CAD$0.0633 with reference to the Bank of Canada closing exchange rate on March 29, 2024) for each Appili Share held (the "Cash Consideration" and together with the Share Consideration collectively, the "Transaction Consideration") representing implied total consideration per Appili Share of approximately US$0.0561(or approximately CAD$0.07598 with reference to the Bank of Canada closing exchange rate on March 29, 2024) based on th
SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Received $1 million from Aditxt, Inc. (NASDAQ:ADTX) in May 2024 in consideration for reinstating and amending
-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch -- SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofe
This strategic acquisition positions Pearsanta for robust growth: expanding opportunities in women's health, spanning endometriosis to ovarian cancer, and in men's health starting with prostate cancer Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the Company and its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired MDNA Life Sciences Inc.'s ("MDNA") proprietary, early disease and cancer detection platform. This strategic move reinforces Pearsanta's dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics. Th
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
3 - Aditxt, Inc. (0001726711) (Issuer)
4 - Aditxt, Inc. (0001726711) (Issuer)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G - Aditxt, Inc. (0001726711) (Subject)
SC 13G - Aditxt, Inc. (0001726711) (Subject)
SC 13G - Aditxt, Inc. (0001726711) (Subject)
SC 13G/A - Aditxt, Inc. (0001726711) (Subject)
SC 13G - Aditxt, Inc. (0001726711) (Subject)
Aditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company's wholly-owned subsidiary Pearsanta, Inc. ("Pearsanta"). Ernie's appointment is intended to accelerate the commercial launch of Test2Treat.me. Test2Treat.me is an end-to-end, business-to-business ("B2B") and direct-to-consumer ("DTC") clinical diagnostic testing services platform for retail pharmacies, physician practices, employee benefit programs, and consumers. "Naming Ernie as
AditxtScore™ continued driving revenue growth in 2022 by adding to its expanding customer base of large physician networks, healthcare systems, independent laboratories, and employer-sponsored programs. Aditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc. ("Pearsanta"), to accelerate the growth of Aditxt's second program, AditxtScore™, through future strategic revenue and growth-oriented transactions. Anthony Voorhies, currently the head of the AditxtScore™ division, will s
Completion of GMP Drug Substances in January for Clinical Trials in H2, 2023 Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. ("Adimune™) and its plans towards submission of a Clinical Trial Application ("CTA") for its immunotherapeutic technology drug candidate, ADI™-100 ("ADI™-100" or "ADI™"). The CTA application will request approval for Adimune™ to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023. A second study is also planned for ty
Aditxt, Inc. ("Aditxt, or the "Company"). (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced key executive management changes to support its growth plans. Corinne Pankovcin, who has served as CFO of Aditxt, has been appointed as President and will work closely with the Company's CEO, Amro Albanna, to execute Aditxt's business strategy. Thomas J. Farley, who has served as Controller and Principal Accounting Officer of Aditxt, has been appointed as CFO. As CFO of Aditxt since July 2020, Ms. Pankovcin, along with the Company's CEO and executive team, has effectively managed the Company's growth as it became publicly traded on
As an independent director, Dr. Chung brings deep expertise in healthcare investment and corporate development Aditx Therapeutics, Inc. ("Aditxt") (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director. "As a new independent director of Aditxt's board, Dr. Chung brings deep insights spanning global scientific, investment and business communities, and these experiences strongly complement our future growth goals," said Amro Albanna, co-founder and CEO of Aditxt. "We look forward to working with Dr. Chung as we establish our portfolio of fi
Dr. Tyan Will Lead and Advance Organ Transplantation Therapeutic Program Mountain View, CA, Jan. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the appointment of Dr. Dolly B. Tyan as Senior Vice President of Clinical Development – Transplantation. In this role, Dr. Tyan will be overseeing Aditxt’s therapeutic program for organ rejection including advancing current candidates towards clinical trials and developing new products for new applica